Ir para o conteúdo principal

BioCryst Pharmaceuticals (NASDAQ: BCRX) — Perfil da empresa, notícias e dados financeiros

Logo de BioCryst Pharmaceuticals
BCRX BioCryst Pharmaceuticals
BioCryst Pharmaceuticals primary media
Perfil da empresa

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (NASDAQ:BCRX) specializes in the discovery, development, and commercialization of treatments for rare and serious diseases. This biotech firm focuses on developing novel therapies that target unmet medical needs, particularly in the areas of hereditary angioedema, autoimmune diseases, and viral infections. An integral part of their operations includes leveraging their unique drug discovery platform to advance a pipeline of promising treatment candidates. BioCryst's commitment to innovation and patient care drives its objective to provide effective solutions that can significantly improve the quality of life for patients dealing with challenging medical conditions.

Resumo

Public USParticipação acionária
1986Ano de fundação
562Funcionários
Durham, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
Durham, US

Produtos e/ou serviços de BioCryst Pharmaceuticals

  • ORLADEYO® (berotralstat), a once-daily oral therapy preventing attacks in hereditary angioedema (HAE) patients.
  • RAPTIVA® (rapivab), an antiviral treatment for influenza.
  • PERAMIVIR, an injectable drug to treat influenza in adults.
  • ALPIVAB™, a treatment for hospitalized patients with COVID-19.
  • GALIDESIVIR, an antiviral in development for hemorrhagic fever viruses and coronaviruses.

equipe executiva do BioCryst Pharmaceuticals

  • Charles K. GayerCEO, President & Director
  • Babar GhiasCFO & Head of Corporate Development
  • Alane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary
  • John RueschChief Technical Operations Officer
  • David W. JenkinsChief Scientific Officer
  • Nick WilderManager of Investor Relations
  • Stephanie AngeliniChief People Officer & Communications Officer
  • William P. SheridanChief Development Officer
  • Yarlagadda S. BabuChief Discovery Officer
  • Jinky Ang RosselliChief Data Innovation Officer

Principais indicadores financeiros

Resultados divulgados pela BioCryst Pharmaceuticals, em USD.

Cap. de mercado
2,1 bi
Receita (TTM)
940,6 mi
P/L
—
LPA (diluído, TTM)
-1.4
Dividend yield
—
Margem de lucro
-40.9%
Receita e lucro anuais da BioCryst Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
874,8 mi341 mi263,9 mi
450,7 mi-2,5 mi-88,9 mi
331,4 mi-103,7 mi-226,5 mi
270,8 mi-148,4 mi-247,1 mi